BrC1C=[C:4]2[C:8](=CC=1)[N:7](S(C1C=CC=CC=1)(=O)=O)[C:6](C(OCC)=O)=[C:5]2[S:25](Cl)(=O)=O.[Cl:29][C:30]1[CH:31]=[C:32]2[C:36](=[CH:37][CH:38]=1)[N:35](S(C1C=CC=CC=1)(=O)=O)[C:34]([C:48]([O:50][CH2:51][CH3:52])=[O:49])=[C:33]2[S:53](Cl)(=[O:55])=[O:54].N1CCOCC1.N1CCSCC1>>[Cl:29][C:30]1[CH:31]=[C:32]2[C:36](=[CH:37][CH:38]=1)[NH:35][C:34]([C:48]([O:50][CH2:51][CH3:52])=[O:49])=[C:33]2[S:53]([N:7]1[CH2:6][CH2:5][S:25][CH2:4][CH2:8]1)(=[O:54])=[O:55]The titled compound was prepared using the procedures described in Steps B and C of Example 2, replacing in Step B ethyl 5-bromo-3-(chlorosulfonyl)-1-(phenylsulfonyl)-1H-indole-2-carboxylate with ethyl 5-chloro-3-(chlorosulfonyl)-1-(phenylsulfonyl)-1H-indole-2-carboxylate, and morpholine with thiomorpholine. Proton NMR for the product was consistent with the titled compound. ESI+MS: 389.1 [M+H]+.